Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Coverage Initiated at Robert W. Baird

Robert W. Baird started coverage on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Rating) in a research report released on Tuesday, The Fly reports. The firm issued an outperform rating and a $5.00 price objective on the stock. Lineage Cell Therapeutics Stock Down 0.7 % Lineage Cell Therapeutics stock opened at $1.37 on Tuesday. […]